
FDA Offers Insight on QbD for Modified-Release Products
FDA’s quality-by-design (QbD) initiative is a systematic approach to designing and developing pharmaceutical formulations and manufacturing processes to ensure predefined product quality.
 FDA’s quality-by-design (QbD) initiative is a systematic approach to designing and developing pharmaceutical formulations and manufacturing processes to ensure predefined product quality. Understanding the critical quality attributes of the ingredients in a formulation, including excipients, and the critical process parameters in the manufacturing process of the finished drug product is crucial for successfully implementing QbD. Pharmaceutical Technology will be holding a live 
The panelists for the webcast include Peter Timmins, PhD, Executive Director, Drug Product Science and Technology, Research And Development, Bristol-Myers Squibb, who will provide insight and case examples of implementing QbD for modified-release formulations. Om Anand, Senior Reviewer and Dissolution Focal Point in the Division of Bioequivalence II, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration and also the Office of Generic Drugs liaison to the United States Pharmacopeia (USP) and USP Expert Panel member, will offer a regulatory perspective on in vitro performance testing of oral modified-release generic products, inclusive of consideration for alcohol-induced dose-dumping. And Rina Chokshi, Project Leader for Controlled Release Technology, FMC Biopolymer, will discuss how to design controlled-release formulations solutions that remain robust in the presence of alcohol and provide further insight about the critical material, formulation and performance attributes of alcohol-resistant coatings.
		Further information on the 
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


